SINDROME DE GUILLAIN BARRE PDF

Management of children with Guillain-Barre syndrome. Jones HR Jr. Guillain-Barre syndrome: perspectives with infants and children. Semin Pediatr Neurol ; 7 2 : Beghi E et al. Guillain-Barre syndrome.

Author:Daijora Grojinn
Country:Somalia
Language:English (Spanish)
Genre:Travel
Published (Last):13 February 2017
Pages:96
PDF File Size:5.62 Mb
ePub File Size:2.19 Mb
ISBN:354-8-18626-623-2
Downloads:46435
Price:Free* [*Free Regsitration Required]
Uploader:Shagar



Management of children with Guillain-Barre syndrome. Jones HR Jr. Guillain-Barre syndrome: perspectives with infants and children. Semin Pediatr Neurol ; 7 2 : Beghi E et al. Guillain-Barre syndrome. Clinicoepidemiologic features and effect of infl uenza vaccine. Arch Neurol ; 42 11 : Occurrence, clinical manifestations, and prognosis of Guillain-Barre syndrome. Arch Dis Child ; 66 6 : ; discussion Olive JM et al. Epidemiologic study of Guillain-Barre syndrome in children Yuki N et al. Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain-Barre syndrome.

Schessl J et al. Infections and vaccinations preceding childhood Guillain-Barre syndrome: a prospective study. Eur J Pediatr ; 9 : Kuroki S et al. Campylobacter jejuni strains from patients with Guillain-Barre syndrome belong mostly to Penner serogroup 19 and contain beta-N-acetylglucosamine residues.

Ann Neurol ; 33 3 : Rees JH et al. Campylobacter jejuni infection and Guillain- Barre syndrome. N Engl J Med ; 21 : McCarthy N, Giesecke J. Incidence of Guillain-Barre syndrome following infection with Campylobacter jejuni. Am J Epidemiol ; 6 : Sheikh KA et al. Molecular mimicry in Guillain-Barre syndrome. Ann N Y Acad Sci ; Chiba A et al.

Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain- Barre syndrome: clinical and immunohistochemical studies. Neurology ; 43 10 : Seroreactivity to Campylobacter jejuni and gangliosides in patients with Guillain- Barre syndrome. J Infect Dis ; 4 : Hao Q et al. Anti-GalNAc-GD1a antibody-associated Guillain- Barre syndrome with a predominantly distal weakness without cranial nerve impairment and sensory disturbance.

Ann Neurol ; 45 6 : Ganglioside composition of the human cranial nerves, with special reference to pathophysiology of Miller Fisher syndrome. Brain Res ; : Assessment of current diagnostic criteria for Guillain-Barre syndrome.

Ann Neurol ; 27 Suppl: S Jones HR. Childhood Guillain-Barre syndrome: clinical presentation, diagnosis, and therapy. J Child Neurol ; 11 1 : Clinical presentation and course of childhood Guillain-Barre syndrome: a prospective multicentre study.

Neuropediatrics ; 38 1 : Pain and the Guillain-Barre syndrome in children under 6 years old. J Pediatr ; 6 : The role of plasmapheresis in childhood Guillain-Barre syndrome. Ann Neurol ; 28 1 : Kleyweg RP et al. The natural history of the Guillain-Barre syndrome in 18 children and 50 adults. J Neurol Neurosurg Psychiatry ; 52 7 : Prognosis in severe Guillain-Barre syndrome. Arch Dis Child ; 62 3 : Prognosis in Guillain-Barre syndrome. Arch Dis Child ; 62 7 : Visser LH et al.

Guillain-Barre syndrome without sensory loss acute motor neuropathy. A subgroup with specifi c clinical, electrodiagnostic and laboratory features.

Dutch Guillain-Barre Study Group. Brain ; Pt 4 : Nachamkin I et al. Patterns of Guillain-Barre syndrome in children: results from a Mexican population.

Neurology ; 69 17 : Ho TW et al. Motor nerve terminal degeneration provides a potential mechanism for rapid recovery in acute motor axonal neuropathy after Campylobacter infection. Neurology ; 48 3 : Feasby TE et al. Severe axonal degeneration in acute Guillain- Barre syndrome: evidence of two different mechanisms?

J Neurol Sci ; 2 : Cytomegalovirus infection and Guillain-Barre syndrome: the clinical, electrophysiologic, and prognostic features. Neurology ; 47 3 : Polo JM et al. Rev Neurol ; 34 9 : Electrodiagnostic abnormalities in consecutive patients with Guillain-Barre syndrome. Arch Neurol ; 47 8 : McKhann GM et al. Clinical and electrophysiological aspects of acute paralytic disease of children and young adults in northern China.

Lancet ; : Bernsen RA et al. Residual physical outcome and daily living 3 to 6 years after Guillain-Barre syndrome. Neurology ; 53 2 : Fletcher DD et al. Long-term outcome in patients with Guillain- Barre syndrome requiring mechanical ventilation. Neurology ; 54 12 : Meythaler JM. Rehabilitation of Guillain-Barre syndrome. Arch Phys Med Rehabil ; 78 8 : Hughes RA et al.

Supportive care for patients with Guillain- Barre syndrome. Arch Neurol ; 62 8 : Lawn ND et al. Anticipating mechanical ventilation in Guillain- Barre syndrome. Arch Neurol ; 58 6 : Hund EF et al.

Intensive management and treatment of severe Guillain-Barre syndrome. Crit Care Med ; 21 3 : Kanra G et al. Intravenous immunoglobulin treatment in children with Guillain-Barre syndrome.

A TEXTBOOK OF ENGINEERING PHYSICS BY AVADHANULU PDF

Síndrome de Guillain-Barré

The demyelinating form of Guillain-Barre syndrome destroys the protective covering of the peripheral nerves myelin sheath , preventing the nerves from transmitting signals to the brain. Weakness and tingling in your extremities are usually the first symptoms. These sensations can quickly spread, eventually paralyzing your whole body. In its most severe form Guillain-Barre syndrome is a medical emergency. Most people with the condition must be hospitalized to receive treatment. The exact cause of Guillain-Barre syndrome is unknown. But two-thirds of patients report symptoms of an infection in the six weeks preceding.

LEY 28857 PDF

Guillain–Barré syndrome

Although the cause is unknown, the underlying mechanism involves an autoimmune disorder in which the body's immune system mistakenly attacks the peripheral nerves and damages their myelin insulation. In those with severe weakness, prompt treatment with intravenous immunoglobulins or plasmapheresis , together with supportive care, will lead to good recovery in the majority of people. This is followed by weakness of the legs and arms that affects both sides equally and worsens over time. The plateau phase can take between two days and six months, but the most common duration is a week. This may consist of upper respiratory tract infection rhinitis, sore throat or diarrhea.

Related Articles